Adverum Biotechnologies (ADVM) Receives a Buy from Chardan Capital

By Austin Angelo

Chardan Capital analyst Gbola Amusa reiterated a Buy rating on Adverum Biotechnologies (ADVMResearch Report) today. The company’s shares closed last Monday at $11.07.

According to TipRanks.com, Amusa is a top 100 analyst with an average return of 22.2% and a 47.8% success rate. Amusa covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Voyager Therapeutics, and Solid Biosciences.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Adverum Biotechnologies with a $18.20 average price target, a 61.3% upside from current levels. In a report issued on March 16, Leerink Partners also initiated coverage with a Buy rating on the stock with a $17.00 price target.

See today’s analyst top recommended stocks >>

Based on Adverum Biotechnologies’ latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $18.93 million. In comparison, last year the company earned revenue of $70K and had a GAAP net loss of $15.66 million.

Based on the recent corporate insider activity of 14 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ADVM in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Adverum Biotechnologies, Inc. is a clinical-stage biotechnology company that engages in the development of novel gene therapies to treat patients with sight-threatening ophthalmic diseases. It focuses on treatment of wet age-related macular degeneration, alpha-1 antitrypsin deficiency, hereditary angioedema, friedreich’s ataxia, severe allergy, color vision deficiency, and juvenile x-linked retinoschisis. The company was founded by Mark S. Blumenkranz, Thomas W. Chalberg, Jr. and Steven Daniel Schwartz on July 17, 2006 and is headquartered in Menlo Park, CA.